Endocyte touts positive Phase 0 results for EC0652

01/29/2013 | RTT News

Endocyte said a Phase 0 study showed its EC0652, an imaging agent for prostate-specific membrane antigen, is safe and effective at targeting diseased cells. Based on the results, the company said it plans to advance the development of EC0652 and its therapeutic agent EC1069. Endocyte said it is looking to file an investigational new drug application for EC1069 by year's end.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC